Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 564 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer September 13, 2022 Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Reflections on Progress and Partnership at ASCO 2026 June 16, 2026 Load more HOT NEWS FDA Approves HPV Tests That Allow for Self-Collection in a Health... FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... Urine test for bladder cancer being developed
